Skip to content

Study · Randomized controlled trial · n = 71 · 2019

6 results

Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial.

Santo A, Pilotto S, Galetta D, Grossi F, Fasola G, Romano G, Bonanno L, Bearz A, Papi M, Roca E, Catino A, Follador A and 9 more

Show all authors

Rijavec E, Genova C, Petrillo P, Favaretto A, Giannone L, Milella M, Tortora G, Giannarelli D, Bria E

Lung cancer (Amsterdam, Netherlands)11 Jun 2019Cited by 6 (Europe PMC)

PMID31319970 (opens in a new tab)DOI10.1016/j.lungcan.2019.06.011 (opens in a new tab)PepBankPUB-31319970
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In SCLC patients, median PFS was 3.6 months with lanreotide versus 2.3 with observation, without a significant difference.

    In plain wordsIn SCLC patients, lanreotide did not significantly prolong survival without progression versus observation.

    Peptide
    Lanreotide
    Outcome
    No significant changePFS overall
    Study

    n = 71

    Comparator
    Observation
    Analysis
    Primary
    Outcome group
    Tumor growth · Cancer
    Studied dose
    120 mg every 28 days · subcutaneous · Up to 1 year or progressionAs given in this study (human).

    Measurements

    Median PFS
    3.6 months
    lanreotide, 95% CI 3.2-3.9
    Median PFS
    2.3 months
    observation, 95% CI 1.7-2.9
    Hazard ratio for PFS
    1.51
    95% CI 0.90-2.50
    P value for PFS
    0.11
    lanreotide versus observation

    Source sentences

    Summary
    Median PFS was 3.6 (95% CI 3.2-3.9) with lanreotide versus 2.3 months (95% CI 1.7-2.9) with observation (HR 1.51, 95% CI 0.90-2.50; P = 0.11).
    2 context sentences
    Summary · context
    A multicenter, randomized, phase 3 trial was conducted in SCLC expressing somatostatine receptors at baseline Octreoscan, responding after platinum-based chemotherapy with/without radiotherapy.
    Summary · context
    Patients were randomized 1:1 to receive maintenance lanreotide 120 mg subcutaneously every 28 days, up to 1 year or progression versus observation.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In SCLC patients, median OS was 9.5 months with lanreotide versus 4.7 with observation (P = 0.47).

    In plain wordsIn SCLC patients, lanreotide did not significantly prolong overall survival versus observation.

    Peptide
    Lanreotide
    Outcome
    No significant changeOverall survival
    Study

    n = 71

    Comparator
    Observation
    Analysis
    Secondary
    Outcome group
    Mortality · Cancer
    Studied dose
    120 mg every 28 days · subcutaneous · Up to 1 year or progressionAs given in this study (human).

    Measurements

    Median overall survival
    9.5 months
    lanreotide, 95% CI 4.8-14.3
    Median overall survival
    4.7 months
    observation
    P value for overall survival
    0.47
    lanreotide versus observation

    Source sentences

    Summary
    Median OS was 9.5 (95% CI 4.8-14.3) with lanreotide versus 4.7 months (95% CI <1-16.6) with observation (P = 0.47).
    2 context sentences
    Summary · context
    A multicenter, randomized, phase 3 trial was conducted in SCLC expressing somatostatine receptors at baseline Octreoscan, responding after platinum-based chemotherapy with/without radiotherapy.
    Summary · context
    Patients were randomized 1:1 to receive maintenance lanreotide 120 mg subcutaneously every 28 days, up to 1 year or progression versus observation.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In limited-stage SCLC, median PFS was 7.0 months with lanreotide versus 3.8 with observation (P = 0.21).

    In plain wordsIn limited-stage SCLC, lanreotide did not significantly prolong survival without progression versus observation.

    Peptide
    Lanreotide
    Outcome
    No significant changePFS limited disease
    Study

    n: not reported in source

    Comparator
    Observation
    Outcome group
    Tumor growth · Cancer
    Studied dose
    120 mg every 28 days · subcutaneous · Up to 1 year or progressionAs given in this study (human).

    Measurements

    Median PFS
    7 months
    limited disease, lanreotide
    Median PFS
    3.8 months
    limited disease, observation
    P value for PFS
    0.21
    limited disease

    Source sentences

    Summary
    Median PFS was 7.0 (95% CI <1-13.5) with lanreotide versus 3.8 months (95% CI <1-8.6) with observation in LD (P = 0.21), and 3.0 (95% CI 2.2-3.8) versus 2.2 (95% 1.7-2.7) in ED (P = 0.19).
    2 context sentences
    Summary · context
    A multicenter, randomized, phase 3 trial was conducted in SCLC expressing somatostatine receptors at baseline Octreoscan, responding after platinum-based chemotherapy with/without radiotherapy.
    Summary · context
    Patients were randomized 1:1 to receive maintenance lanreotide 120 mg subcutaneously every 28 days, up to 1 year or progression versus observation.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In extended-stage SCLC, median PFS was 3.0 months with lanreotide versus 2.2 with observation (P = 0.19).

    In plain wordsIn extended-stage SCLC, lanreotide did not significantly prolong survival without progression versus observation.

    Peptide
    Lanreotide
    Outcome
    No significant changePFS extended disease
    Study

    n: not reported in source

    Comparator
    Observation
    Outcome group
    Tumor growth · Cancer
    Studied dose
    120 mg every 28 days · subcutaneous · Up to 1 year or progressionAs given in this study (human).

    Measurements

    Median PFS
    3 months
    extended disease, lanreotide, 95% CI 2.2-3.8
    Median PFS
    2.2 months
    extended disease, observation, 95% CI 1.7-2.7
    P value for PFS
    0.19
    extended disease

    Source sentences

    Summary
    Median PFS was 7.0 (95% CI <1-13.5) with lanreotide versus 3.8 months (95% CI <1-8.6) with observation in LD (P = 0.21), and 3.0 (95% CI 2.2-3.8) versus 2.2 (95% 1.7-2.7) in ED (P = 0.19).
    2 context sentences
    Summary · context
    A multicenter, randomized, phase 3 trial was conducted in SCLC expressing somatostatine receptors at baseline Octreoscan, responding after platinum-based chemotherapy with/without radiotherapy.
    Summary · context
    Patients were randomized 1:1 to receive maintenance lanreotide 120 mg subcutaneously every 28 days, up to 1 year or progression versus observation.
  5. 05HumanNon-randomized trialSafety outcome

    In SCLC patients receiving lanreotide, treatment-related adverse events occurred in 28%.

    In plain wordsIn SCLC patients receiving lanreotide, treatment-related adverse events occurred in 28%.

    Peptide
    Lanreotide
    Outcome
    Not applicableTreatment-related adverse events
    Study

    n = 39

    Analysis
    Secondary
    Outcome group
    Adverse events · Cancer
    Studied dose
    120 mg every 28 days · subcutaneous · Up to 1 year or progressionAs given in this study (human).

    Measurements

    Patients with treatment-related adverse events
    28%
    lanreotide arm

    Source sentences

    Summary
    Treatment-related adverse events occurred in 28% of patients with lanreotide (grade 3 in two patients).
    2 context sentences
    Summary · context
    A multicenter, randomized, phase 3 trial was conducted in SCLC expressing somatostatine receptors at baseline Octreoscan, responding after platinum-based chemotherapy with/without radiotherapy.
    Summary · context
    Patients were randomized 1:1 to receive maintenance lanreotide 120 mg subcutaneously every 28 days, up to 1 year or progression versus observation.
  6. 06HumanNon-randomized trialSafety outcome

    In SCLC patients receiving lanreotide, two patients experienced grade 3 treatment-related adverse events.

    In plain wordsIn SCLC patients receiving lanreotide, two patients experienced grade 3 treatment-related adverse events.

    Peptide
    Lanreotide
    Outcome
    Not applicableGrade 3 adverse events
    Study

    n = 39

    Analysis
    Secondary
    Outcome group
    Adverse events · Cancer
    Studied dose
    120 mg every 28 days · subcutaneous · Up to 1 year or progressionAs given in this study (human).

    Measurements

    Patients with grade 3 treatment-related adverse events
    2 patients
    lanreotide arm

    Source sentences

    Summary
    Treatment-related adverse events occurred in 28% of patients with lanreotide (grade 3 in two patients).
    2 context sentences
    Summary · context
    A multicenter, randomized, phase 3 trial was conducted in SCLC expressing somatostatine receptors at baseline Octreoscan, responding after platinum-based chemotherapy with/without radiotherapy.
    Summary · context
    Patients were randomized 1:1 to receive maintenance lanreotide 120 mg subcutaneously every 28 days, up to 1 year or progression versus observation.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.